DOI: 10.36347/sjams.2023.v11i03.022

Pages: 614-619

Background: Ozenoxacin, a novel topical antibacterial agent with incredible bactericidal recreation in opposition to gram-positive bacteria, has been established as a cream with 1% energetic drug for the cure of Adult and Paediatric Patients. Objectives: The aim of this study is to assess the efficacy and safety level of ozenoxacin in the treatment of bacterial skin diseases in adult and paediatric patients. Methods: This is an observational study. This study was carried out on 130 patients the find out about the population including male and female patients in the Department of Dermatology, US-Bangla Medical College Hospital, Narayangonj, Bangladesh. The duration of the period from June 2021 to May 2022. The period from Data was entered in MS Excel and Statistical analysis was done using SPSS-24. Results: This study shows that according to age of 130 Patients aged ≥2 months to <18 years. Here according to Age distribution. Skin diseases were 35.1%, 52.6%, 11.4% when age was ≥2 months to < 12 months. When age was 12 months to <18 years, skin diseases were 26.1%, 65.2%, 8.7%. And skin diseases were 46.4%, 42%, 11.6% when age was ≥18 years.The Pathogens isolated chart (n=130). Here Staphylococcus aureus were 55.8%, Streptococcus pyogenes were 9.2% and other pathogens were 55.8%. Conclusion: Topical ozenoxacin is active and well-tolerated in the treatment of Adult and Paediatric Patients. This impact is demonstrated by rapid onset of response and most efficient medical and microbiological response. Topical ozenoxacin represents a novel option for the treatment.